Predictive Oncology Return on Tangible Equity 2010-2024 | POAI
Current and historical return on tangible equity values for Predictive Oncology (POAI) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Predictive Oncology Return On Tangible Equity Historical Data |
Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
2024-09-30 |
$-0.01B |
$0.00B |
-288.89% |
2024-06-30 |
$-0.01B |
$0.00B |
-192.59% |
2024-03-31 |
$-0.01B |
$0.00B |
-151.35% |
2023-12-31 |
$-0.01B |
$0.01B |
-101.96% |
2023-09-30 |
$-0.02B |
$0.01B |
-110.77% |
2023-06-30 |
$-0.02B |
$0.01B |
-95.00% |
2023-03-31 |
$-0.03B |
$0.02B |
-104.17% |
2022-12-31 |
$-0.03B |
$0.02B |
-96.15% |
2022-09-30 |
$-0.03B |
$0.03B |
-90.09% |
2022-06-30 |
$-0.03B |
$0.03B |
-80.00% |
2022-03-31 |
$-0.02B |
$0.03B |
-51.70% |
2021-12-31 |
$-0.02B |
$0.03B |
-53.33% |
2021-09-30 |
$-0.02B |
$0.05B |
-78.63% |
2021-06-30 |
$-0.03B |
$0.05B |
-147.06% |
2021-03-31 |
$-0.03B |
$0.03B |
-800.00% |
2020-12-31 |
$-0.03B |
$-0.00B |
432.00% |
2020-09-30 |
$-0.03B |
$-0.00B |
413.79% |
2020-06-30 |
$-0.03B |
$-0.01B |
327.27% |
2020-03-31 |
$-0.02B |
$-0.01B |
283.87% |
2019-12-31 |
$-0.02B |
$-0.01B |
347.83% |
2019-09-30 |
$-0.01B |
$-0.01B |
225.00% |
2019-06-30 |
$-0.01B |
$-0.01B |
533.33% |
2019-03-31 |
$-0.01B |
$-0.00B |
-1466.67% |
2018-12-31 |
$-0.01B |
$-0.00B |
-444.44% |
2018-09-30 |
$-0.01B |
$0.00B |
-246.15% |
2018-06-30 |
$-0.01B |
$0.00B |
-184.62% |
2018-03-31 |
$-0.01B |
$0.01B |
-215.38% |
2017-12-31 |
$-0.01B |
$0.00B |
-200.00% |
2017-09-30 |
$-0.01B |
$0.00B |
-240.00% |
2017-06-30 |
$-0.01B |
$0.00B |
-300.00% |
2017-03-31 |
$-0.01B |
$0.00B |
-400.00% |
2016-12-31 |
$-0.01B |
$0.00B |
-700.00% |
2016-09-30 |
$-0.01B |
$0.00B |
-457.14% |
2016-06-30 |
$-0.01B |
$0.00B |
-246.15% |
2016-03-31 |
$-0.01B |
$0.00B |
-400.00% |
2015-12-31 |
$-0.00B |
$0.00B |
800.00% |
2015-09-30 |
$-0.00B |
$0.01B |
133.33% |
2015-06-30 |
$-0.00B |
$-0.01B |
72.73% |
2015-03-31 |
$-0.01B |
$-0.01B |
105.26% |
2014-12-31 |
$-0.01B |
$-0.01B |
186.67% |
2014-09-30 |
$-0.01B |
$-0.00B |
233.33% |
2014-06-30 |
$-0.01B |
$-0.00B |
444.44% |
2014-03-31 |
$-0.01B |
$-0.00B |
360.00% |
2013-12-31 |
$-0.01B |
$-0.00B |
327.27% |
2013-09-30 |
$-0.01B |
$-0.00B |
327.27% |
2013-06-30 |
$-0.01B |
$-0.00B |
266.67% |
2013-03-31 |
$-0.01B |
$-0.00B |
360.00% |
2012-12-31 |
$-0.01B |
$-0.00B |
320.00% |
2012-09-30 |
$-0.01B |
$-0.00B |
360.00% |
2012-06-30 |
$-0.01B |
$-0.00B |
254.55% |
2012-03-31 |
$-0.01B |
$-0.00B |
166.67% |
2011-12-31 |
$-0.00B |
$-0.00B |
145.45% |
2011-09-30 |
$-0.00B |
$-0.00B |
40.00% |
2011-06-30 |
$0.00B |
$-0.00B |
0.00% |
2011-03-31 |
$0.00B |
$-0.00B |
0.00% |
2010-12-31 |
$-0.00B |
$-0.00B |
44.44% |
2010-09-30 |
$-0.00B |
$-0.00B |
44.44% |
2010-06-30 |
$-0.00B |
$-0.00B |
88.89% |
2010-03-31 |
$-0.00B |
$-0.00B |
171.43% |
2009-12-31 |
$-0.00B |
$-0.00B |
300.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical Information Systems |
$0.005B |
$0.002B |
Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS.
|